Interventional Oncology Devices Market Report 2025

The interventional oncology devices market size has grown strongly in recent years. It will grow from $2.39 billion in 2024 to $2.52 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to aging population pool, an increase in cancer prevalence, increase in pharmaceutical R&D expenditure, increased healthcare expenditure and growth in the number of healthcare facilities.

The interventional oncology devices market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing older population, increasing preference towards minimally invasive surgeries (MIS), increasing research and development spending, a rise in healthcare expenditure, high potential in emerging economies and increasing prevalence of cancer and chronic diseases. Major trends in the forecast period include focusing on developing advanced image-guided oncology devices, utilizing ai to develop innovative devices, developing new, innovative embolic devices to enable improved oncology procedures, focusing on using robotics technology and collaborating with other companies and research institutes to accelerate product development and innovation.

Leading companies in the interventional oncology devices market are focusing on advancements in technologies, such as tissue volume, to improve diagnostic accuracy and treatment efficacy in cancer procedures. Tissue volume refers to the quantity of biological tissue obtained during a biopsy. Collecting larger tissue samples allows for more thorough analysis, enhancing diagnostic precision and aiding in effective treatment planning. For example, in June 2023, Argon Medical, a U.S.-based medical device company, introduced the SuperCore Advantage semi-automatic biopsy device. The SuperCore Advantage collects up to 35% more tissue than competing products, reducing the need for multiple biopsy passes, which is essential for acquiring sufficient tissue for accurate diagnosis.

The high prevalence of cancer is expected to drive the growth of the interventional oncology devices market. Cancer is a group of diseases characterized by uncontrolled cell growth, leading to the formation of masses or tumors. This high prevalence creates a demand for interventional oncology devices, essential for diagnosing, treating, and managing cancer, enabling early detection, staging, and monitoring. For instance, in July 2024, the Australian Institute of Health and Welfare reported an increase in cancer diagnoses in Australia from 160,570 cases in 2022 to 164,694 in 2023, marking a significant year-over-year rise. This trend underscores the growing cancer prevalence, supporting the demand for interventional oncology devices in the market.

Companies in the interventional oncology devices market are increasingly incorporating robotics technology to enhance efficiency. Robotic systems integrate image-based planning and navigation, allowing accurate and efficient installation of instruments to specific body parts. In March 2022, the U.S. Food and Drug Administration approved Quantum Surgical’s Epione interventional oncology robotics platform, showcasing the industry's commitment to technological advancements.

Major players in the interventional oncology devices market are focused on innovation, such as AI-powered digital pathology solutions, to enhance the accuracy of breast cancer diagnosis. Paige AI Inc., a U.S.-based biotechnology company, launched Paige Breast Lymph Node in March 2022, an AI-powered digital pathology solution improving the detection of breast cancer metastases in lymph node tissue. This technology offers AI-driven detection capabilities, a convenient heat map overlay, high sensitivity and specificity, seamless integration into existing workflows, user-friendliness, and robust security measures.

In August 2022, Boston Scientific Corporation acquired Obsidio Inc. for an undisclosed amount, aiming to expand its interventional oncology portfolio and strengthen its position in the growing market. Obsidio Inc., a U.S.-based medical device company, specializes in developing minimally invasive interventional oncology devices for treating liver cancer and other solid tumors.

Major companies operating in the interventional oncology devices market include Boston Scientific Corporation, Terumo Corporation, Siemens Healthineers, Sirtex Medical Limited, Henlius, Viant Medical, AngioDynamics Inc., Pfizer, Steris Applied Sterilization Technologies, Dr.Reddys, CapeRay, Innovent Biologics, Novartis AG, Consonance, ABLbio, Adimmune, Heraeus Medical, Bioavlee, Mediceena International, Sinapi biomedical, Olympus, Freudenberg Medical, Hisun Pharma, Beijing ShuangLu Pharmaceuticals, Edwards LifeSciences Corp, Gulf Dent Trading, LifeTech Scientific Corporation, Biomerics, Medtronic plc, Dickinson & Company, 3M Company, DISA Vascular, Johnson & Johnson, Eurolab, Koninklijke Philips, Quantum SurgicalKyowa Hakko Kirin, Viatris, Nipro, Zimmer Biomet Holdings, Profound Medical, Gedeon Richter, Baxter, Ti-TaMED, Abbott Laboratories, Cook Medical LLC, Adavium Medical, Autocam Medical, Bio-Thera, Stryker, GE Healthcare, Sonic Healthcare, Medicem, HealthTronics, Bayer AG, Intuitive Surgical Inc, Aster DM Healthcare, Danaher Corporation, Varian Medical Systems Inc., Smileneo, EDAP TMS S.A, Fresenius Medical Care AG, China Regenerative Medicine International.

North America was the largest region in the interventional oncology devices market in 2024. Asia-Pacific was the second largest region in the global interventional oncology devices market report. The regions covered in the interventional oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional oncology devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Interventional oncology devices are specialized medical tools and technologies designed for the minimally invasive diagnosis and treatment of cancer. These devices enable direct targeting of tumors, allowing for treatments such as ablation or embolization, which focus on destroying cancer cells while preserving nearby healthy tissue.

The primary products within the field of interventional oncology devices include embolization devices, ablation devices, and support devices. Embolization devices are designed for the embolization of blood vessels associated with various tumors. These devices are employed in procedures such as thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. These procedures are applied in the treatment of various cancer types, including liver cancer, kidney cancer, lung cancer, bone cancer, and others.

The interventional oncology devices market research report is one of a series of new reports that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.